The combination of nonthyroidal illness syndrome and renal dysfunction further increases mortality risk in patients with acute myocardial infarction: a prospective cohort study

Table 3 Comparison of Hazard Ratio of all-cause and cardiovascular mortality

	Normal Group	NTIS Group			Renal dysfunction Group			Combined Group
	HR (95% CI)	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
All-cause mortality
Model 1	1	1.912	1.219–2.998	0.005	1.514	1.056–2.170	0.024	3.209	2.157–4.774	< 0.001
Model 2	1	2.036	1.252–3.312	0.004	1.675	1.090–2.572	0.019	3.488	2.223–5.471	< 0.001
Model 3	1	2.138	1.234–3.704	0.007	2.050	1.271–3.307	0.003	4.140	2.534–6.764	< 0.001
Cardiovascular mortality
Model 1	1	1.903	1.010–3.587	0.047	1.730	1.074–2.788	0.024	3.955	2.387–6.553	< 0.001
Model 2	1	2.141	1.087–4.217	0.028	2.089	1.185–3.684	0.011	4.580	2.578–8.136	< 0.001
Model 3	1	2.134	1.028–4.430	0.042	2.237	1.210–4.135	0.010	5.152	2.786–9.527	< 0.001

Model1: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy (use of antiplatelet agents, β-Blockers, LLDs, ACEIs/ARBs, CCBs, and Diuretics), and BMI (for all patients)
Model2: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG) (for all patients)
Model3: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG), WBC, Hb, Alb, TC, TG, HDL-c, LDL-c, FPG and CRP (for all patients)

ISSN: 1471-2261